Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT06801054
Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First Dose (DoubleDoseTNK)
Sponsor: Genentech, Inc.
Conditions
Acute Ischemic Stroke
Interventions
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
Updated 2 times since 2025 Last updated: Jun 3, 2025 Started: Jul 1, 2025 Primary completion: Jun 30, 2026 Completion: Sep 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Acute Ischemic Stroke and is currently actively recruiting participants. Genentech, Inc. leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
2 versions recorded-
Jul 2025 — Present [monthly]
Not Yet Recruiting PHASE1
-
Feb 2025 — Jul 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Genentech, Inc.
- Grotta Stroke Research Foundation
- Memorial Hermann Health System
- Memorial Hermann Hospital Mobile Stroke Unit
- The University of Texas Health Science Center, Houston
Data source: Memorial Hermann Health System
For direct contact, visit the study record on ClinicalTrials.gov .